ASCO GI 2023 Conference Coverage
Playback speed
10 seconds
ASCO GI 2023 Results From a Phase 1a/1b Study: Botensilimab, a Novel Innate/Adaptive Immune Activator, + Balstilimab in Metastatic Heavily Pretreated Microsatellite Stable CRC
By
ASCO GI 2023 Conference Coverage
FEATURING
Anthony El-Khoueiry
By
ASCO GI 2023 Conference Coverage
FEATURING
Anthony El-Khoueiry
157 views
January 25, 2023
Comments 0
Login to view comments.
Click here to Login
Videos